



# Identification of a Novel Cobamide Remodeling Enzyme in the Beneficial Human Gut Bacterium *Akkermansia muciniphila*

 Kenny C. Mok,<sup>a</sup>  Olga M. Sokolovskaya,<sup>a\*</sup>  Alexa M. Nicolas,<sup>a</sup>  Zachary F. Hallberg,<sup>a</sup> Adam Deutschbauer,<sup>b</sup>  
 Hans K. Carlson,<sup>b</sup>  Michiko E. Taga<sup>a</sup>

<sup>a</sup>Department of Plant & Microbial Biology, University of California, Berkeley, Berkeley, California, USA

<sup>b</sup>Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA

**ABSTRACT** The beneficial human gut bacterium *Akkermansia muciniphila* provides metabolites to other members of the gut microbiota by breaking down host mucin, but most of its other metabolic functions have not been investigated. *A. muciniphila* strain Muc<sup>T</sup> is known to use cobamides, the vitamin B<sub>12</sub> family of cofactors with structural diversity in the lower ligand. However, *A. muciniphila* Muc<sup>T</sup> is unable to synthesize cobamides *de novo*, and the specific forms that can be used by *A. muciniphila* have not been examined. We found that the levels of growth of *A. muciniphila* Muc<sup>T</sup> were nearly identical with each of seven cobamides tested, in contrast to nearly all bacteria that had been studied previously. Unexpectedly, this promiscuity is due to cobamide remodeling—the removal and replacement of the lower ligand—despite the absence of the canonical remodeling enzyme CbiZ in *A. muciniphila*. We identified a novel enzyme, CbiR, that is capable of initiating the remodeling process by hydrolyzing the phosphoribosyl bond in the nucleotide loop of cobamides. CbiR does not share similarity with other cobamide remodeling enzymes or B<sub>12</sub>-binding domains and is instead a member of the apurinic/apyrimidinic (AP) endonuclease 2 enzyme superfamily. We speculate that CbiR enables bacteria to repurpose cobamides that they cannot otherwise use in order to grow under cobamide-requiring conditions; this function was confirmed by heterologous expression of *cbiR* in *Escherichia coli*. Homologs of CbiR are found in over 200 microbial taxa across 22 phyla, suggesting that many bacteria may use CbiR to gain access to the diverse cobamides present in their environment.

**IMPORTANCE** Cobamides, comprising the vitamin B<sub>12</sub> family of cobalt-containing cofactors, are required for metabolism in all domains of life, including most bacteria. Cobamides have structural variability in the lower ligand, and selectivity for particular cobamides has been observed in most organisms studied to date. Here, we discovered that the beneficial human gut bacterium *Akkermansia muciniphila* can use a diverse range of cobamides due to its ability to change the cobamide structure via a process termed cobamide remodeling. We identify and characterize the novel enzyme CbiR that is necessary for initiating the cobamide remodeling process. The discovery of this enzyme has implications for understanding the ecological role of *A. muciniphila* in the gut and the functions of other bacteria that produce this enzyme.

**KEYWORDS** *Akkermansia muciniphila*, cobalamin, cobamide remodeling, corrinoids, vitamin B12

The human gut microbiota is composed of diverse communities of microbes that play important roles in human health (1–4). Disruption of the composition of the microbiota, known as dysbiosis, is associated with numerous disease states (5–9). While the immense complexity and interindividual variability of the microbiota have made it challenging to identify the specific functions of most community members,

**Citation** Mok KC, Sokolovskaya OM, Nicolas AM, Hallberg ZF, Deutschbauer A, Carlson HK, Taga ME. 2020. Identification of a novel cobamide remodeling enzyme in the beneficial human gut bacterium *Akkermansia muciniphila*. *mBio* 11:e02507-20. <https://doi.org/10.1128/mBio.02507-20>.

**Editor** Katherine P. Lemon, Baylor College of Medicine

**Copyright** © 2020 Mok et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Address correspondence to Michiko E. Taga, [taga@berkeley.edu](mailto:taga@berkeley.edu).

\* Present address: Olga M. Sokolovskaya, Department of Infectious Diseases, Genentech, South San Francisco, California, USA.

**Received** 1 September 2020

**Accepted** 28 October 2020

**Published** 8 December 2020



**FIG 1** Cobamide structures. (A) Structure of pCbl. All cobamides are composed of a corrin ring containing a central cobalt ion and an upper (R) and lower ligand. In pCbl, the lower ligand is adenine. The lower ligand and the ribose and phosphate moieties comprise the nucleotide loop, which is covalently attached to the corrin ring via an aminopropanol linker. The bonds hydrolyzed by the CbiZ amidohydrolase and the CbiR phosphodiesterase and degradation products are together known as corrinoids. (B) Upper ligands (R) in cobamides, the catalytic center of the cofactor; prefixes used in the text to denote the upper ligand are shown in parentheses. (C) The three chemical classes of lower ligands present in cobamides. The structures of the seven cobamide lower ligands used in this study are shown. The names of the lower ligand base and abbreviations used for the corresponding cobamides are given below the structures.

particular taxa are starting to be linked to health and disease (10–12), with the bacterium *Akkermansia muciniphila* recently emerging as a beneficial microbe due to its distinctive metabolic capabilities (13, 14).

*A. muciniphila* is thought to benefit the host by inducing mucus production, improving gut barrier function, and stimulating a health-promoting inflammatory response (15–24). *A. muciniphila* is one of few bacterial species capable of using mucin, the main component of mucus, as a sole carbon, nitrogen, and energy source (25). Mucin degradation products released by *A. muciniphila* are used as carbon sources by butyrate-producing bacteria and likely other bacteria, and for this reason *A. muciniphila* is thought to be a keystone species in the gut (26, 27). In addition to providing metabolites to neighboring microbes, in coculture *A. muciniphila* can use a cobamide cofactor, pseudocobalamin (pCbl; Fig. 1A), provided by *Eubacterium hallii* for the production of propionate (26). Both butyrate and propionate positively affect host metabolism and immune function (28–30). Along with the enzyme methylmalonyl-coenzyme A mutase (MCM), which is required for propionate production, nearly all *A. muciniphila* strains have homologs of three other cobamide-dependent enzymes, methionine synthase (Meth), ribonucleotide reductase (NrdJ), and epoxyqueuosine reductase (QueG) (31).

Cobamides are a family of cobalt-containing corrinoid cofactors that include B<sub>12</sub> (cobalamin [Cbl]), an essential micronutrient for humans. Cobamides are required by organisms in all domains of life but are synthesized by only a subset of prokaryotes (32–34). While some strains of *A. muciniphila* have been shown or are predicted to produce cobamides *de novo*, the type strain, Muc<sup>T</sup>, is incapable of *de novo* cobamide production (31). Instead, strain Muc<sup>T</sup> and most other *A. muciniphila* strains are predicted to be capable of cobinamide (Cbi; Fig. 1A) salvaging (31, 34), a process in which a cobamide is synthesized from the late precursor Cbi (35). Thus, the four cobamide-dependent metabolic pathways present in *A. muciniphila* function in most strains, including Muc<sup>T</sup>, only when a cobamide or a late precursor such as Cbi is provided by another organism. Several other human gut bacterial species have similarly been found to use

cobamide cofactors but to be unable to produce them *de novo*, including *Bacteroides fragilis*, *Bacteroides thetaiotaomicron*, *Bacteroides vulgatus*, *Clostridioides difficile*, *Enterococcus faecalis*, *Escherichia coli*, and *Parabacteroides distasonis* (36–40). In addition to these specific examples, genomic analysis suggests that dependence on cobamide-producing microbes is widespread in the gut and other environments: 58% of human gut bacteria and 49% of all sequenced bacteria are predicted to use cobamides but to lack the capacity to produce them *de novo* (34).

A feature that sets cobamides apart from other enzyme cofactors is that different microbes produce structurally distinct cobamides (41). This variability is mostly limited to the lower ligand, which can be benzimidazolyl, purinyl, or phenolyl bases (Fig. 1C). Individual cobamide-producing bacteria typically synthesize only one type of cobamide, but microbial communities have been found to contain four to eight different cobamides or cobamide precursors (42–45). A study of 20 human subjects showed that the human gut is dominated by the purinyl class of cobamides, with benzimidazolyl and phenolyl cobamides and Cbi also present (42). The structural diversity in cobamides impacts growth and metabolism, as most organisms studied to date, including both cobamide producers and auxotrophs, are selective in their cobamide use (39, 46–54). For example, the human gut bacterium *B. thetaiotaomicron* can use benzimidazolyl and purinyl cobamides but not phenolyl cobamides (37); *Dehalococcoides mccartyi* is selective for particular benzimidazolyl cobamides (55, 56); many eukaryotic algae prefer Cbl to pCbl (57); and *Sporomusa ovata* requires phenolyl cobamides (58). Thus, microbes that depend on cobamides produced by others may struggle to grow in environments lacking their preferred cobamides. However, some organisms have evolved mechanisms for acquiring the specific cobamides that function in their metabolism. For example, bacterial cobamide uptake can be somewhat selective, as shown in a study in *B. thetaiotaomicron* (37). Another strategy used by some microbes is cobamide remodeling, i.e., the removal and replacement of the lower ligand.

Cobamide remodeling was first described in *Rhodobacter sphaeroides* (59) but has also been observed in the bacteria *D. mccartyi* and *Vibrio cholerae* and the algae *Pavlova lutheri* and *Chlamydomonas reinhardtii* (45, 48, 56, 57). In each case, cobamide remodeling enables the organism to repurpose a cobamide that supports growth poorly. In *R. sphaeroides*, the cobamide remodeling process is initiated by the enzyme CbiZ, which hydrolyzes the amide bond adjacent to the aminopropanol linker (Fig. 1A) (59); in subsequent steps, cobamide biosynthesis is completed with a different lower ligand via the activity of six gene products, most of which are also required for Cbi salvaging. *In vitro*, *R. sphaeroides* CbiZ hydrolyzes pCbl but not Cbl (59). This specificity is thought to drive the conversion of pCbl, a cofactor that *R. sphaeroides* cannot use, into Cbl, which functions in its metabolism. *D. mccartyi* also has homologs of *cbiZ* (56), while cobamide remodeling in *V. cholerae* was recently shown to involve the cobamide biosynthesis enzyme CobS (48). The genes required for cobamide remodeling in algae have not been identified. Nevertheless, cobamide remodeling has not been found to be widespread; it has rarely been observed in cultured bacteria, and over 90% of corrinoid-requiring bacteria, including *A. muciniphila*, lack a homolog of *cbiZ* (34).

Here, we show that *A. muciniphila* strain Muc<sup>T</sup> is able to grow equivalently when provided a variety of cobamides. We found that this lack of selectivity is due to the unexpected ability of *A. muciniphila* to remodel cobamides. We identified a previously uncharacterized phosphodiesterase in *A. muciniphila* that we named CbiR and which initiates the remodeling process by hydrolyzing cobamides. Heterologous expression in *E. coli* shows that CbiR expands access to a cobamide that does not otherwise support growth. Homologs of CbiR are present in the genomes of microbes in diverse habitats from 22 phyla, and phylogenetic analysis establishes CbiR as a new, distinct clade within the AP endonuclease 2 superfamily. These observations enhance the understanding of the metabolic roles of *A. muciniphila* and improve our ability to predict cobamide-dependent physiology in other bacteria.


## RESULTS

**A. muciniphila strain Muc<sup>T</sup> salvages Cbi to produce pCbl.** *A. muciniphila* strain Muc<sup>T</sup> lacks most of the genes required for cobamide synthesis and does not produce cobamides *de novo* (31), but it is predicted to be capable of Cbi salvaging (34). To test this prediction, we extracted corrinoids from *A. muciniphila* cultured with and without Cbi and analyzed the corrinoid composition of the samples by high-performance liquid chromatography (HPLC). Cultured without Cbi, no corrinoids were detected in the extractions (Fig. 2A). However, when Cbi was added to the growth medium, a cobamide with the same retention time and a UV-visible light (UV-Vis) spectrum nearly identical to that of pCbl was detected by HPLC (Fig. 2A). Mass spectrometry (MS) analysis confirmed that this cobamide is pCbl (see Fig. S1 in the supplemental material).


**A. muciniphila strain Muc<sup>T</sup> does not show cobamide selectivity.** Having established that *A. muciniphila* strain Muc<sup>T</sup> cannot synthesize cobamides without the addition of a precursor, we next examined which cobamides it is capable of using by measuring growth in the presence of various cobamides under a cobamide-requiring condition. *A. muciniphila* strain Muc<sup>T</sup> has four cobamide-dependent enzymes; however, MCM is not required for laboratory growth (60), QueG function does not affect growth in other bacteria (61), and the cobamide-independent ribonucleotide reductase NrdDG likely renders NrdJ nonessential. Because *A. muciniphila* lacks a homolog of the cobamide-independent methionine synthase MetE (34), growth in the absence of methionine is expected to be dependent on the cobamide-dependent methionine synthase MetH. Thus, growth in methionine-deplete medium is predicted to require cobamide addition. We found this to be the case, as addition of Cbi or any of the seven cobamides tested was necessary to support growth of *A. muciniphila* (Fig. 2B). Surprisingly, however, *A. muciniphila* showed essentially no cobamide selectivity, with less than 2-fold variations in the cobamide concentrations resulting in half-maximal growth (EC<sub>50</sub>) (Fig. 2B).

**A. muciniphila strain Muc<sup>T</sup> remodels cobamides to pCbl.** The ability of all of the tested cobamides to support nearly identical levels of growth of *A. muciniphila* could have been due to promiscuity in its cobamide-dependent methionine synthase. Alternatively, *A. muciniphila* might remodel cobamides, despite the absence of a homolog of *cbiZ* in its genome. If cobamide remodeling occurs in *A. muciniphila*, exogenously supplied cobamides would be altered by the bacterium. Therefore, we extracted corrinoids from *A. muciniphila* cultures supplemented with Cbl, [Cre]Cba, or [MeAde]Cba to determine whether the added cobamides could be recovered. HPLC analysis revealed that none of the Cbl or [Cre]Cba and only half of the [MeAde]Cba remained in the extractions. This loss of the added cobamide coincided with the appearance of a new cobamide that coeluted with pCbl (Fig. 2C). MS analysis confirmed that this cobamide was indeed pCbl (Fig. S2). These results demonstrate that *A. muciniphila* remodels cobamides to pCbl.

**Identification and characterization of a novel cobamide remodeling enzyme in *A. muciniphila*.** The identification of cobamide remodeling activity despite the absence of a *cbiZ* homolog in the genome suggested that a novel enzyme capable of hydrolyzing cobamides is present in *A. muciniphila*. We reasoned that the gene encoding this enzyme might be located near the cobamide biosynthesis and salvaging genes *cobDQ*, *cbiB*, *cobT*, *cobS*, and *cobU*, some or all of which would be required for completion of the remodeling process. These five genes are found at a single locus in the *A. muciniphila* genome that also contains an open reading frame (ORF) with unknown function, annotated as Amuc\_1679 (GenBank accession no. [ACD05497.1](https://www.ncbi.nlm.nih.gov/nuccore/ACD05497.1)) (Fig. 3A). Amuc\_1679 is predicted to encode a protein with a conserved ( $\beta/\alpha$ )<sub>8</sub> TIM barrel domain from the apurinic/aprimidinic (AP) endonuclease 2 superfamily (pfam01261). This superfamily is composed of several enzymes, including endonuclease IV, which hydrolyzes phosphodiester bonds at AP sites in DNA (62). The proximity of Amuc\_1679 to genes involved in cobamide biosynthesis and the presence of a phosphodiester bond connecting the lower ligand to the aminopropanol linker suggested that Amuc\_1679 might play a role in cobamide biology in *A. muciniphila*. Further, homologs of this gene



**FIG 2** *A. muciniphila* strain *Muc*<sup>T</sup> can salvage Cbi and remodel cobamides. (A) HPLC analysis of corrinoid extractions from *A. muciniphila* grown with methionine in the presence or absence of 10 nM Cbi for 72 h showed that *A. muciniphila* can salvage Cbi. Standards for Cbi and pCbl are shown at the bottom. Note that Cbi appears as two peaks. Comparison of UV-Vis spectra (inset) of the HPLC peaks at 8.8 min shows that the corrinoid produced by *A. muciniphila* (*A.m.*) grown with Cbi (thick line) is similar to a pCbl standard (std) (thin line) and not a Cbi standard (dashed line). Spectra were normalized to each other based on their maxima to aid comparison. mAU, milli arbitrary units. (B) *A. muciniphila* growth under methionine-deplete conditions. The OD<sub>600</sub> values shown were determined for saturated cultures after 29 h of growth with the indicated concentrations of each corrinoid. EC<sub>50</sub> values and the corresponding 95% confidence intervals for each corrinoid are given in the table. Data points and error bars represent means and standard deviations, respectively, of results from three biological replicates. The results are representative of three independent experiments. (C) HPLC analysis of corrinoid extractions from *A. muciniphila* grown with 10 nM Cbl, [MeAde]Cba, or [Cre]Cba for 72 h showed that *A. muciniphila* remodels cobamides to pCbl. Cobamide standards are shown at the bottom, with [Cre]Cba appearing as two peaks.



**FIG 3** Purified CbiR hydrolyzes AdoCbl to form AdoCbi-P and  $\alpha$ -ribazole *in vitro*. (A) *A. muciniphila* Amuc\_1679 (*cbiR*) and homologs in other bacteria (black arrows) are located near cobamide biosynthesis genes (white arrows). An expanded genomic comparison is shown in Fig. S3. (B) Purified CbiR converts AdoCbl to another corrinoid compound *in vitro* in the absence of oxygen. Results of HPLC analysis of reaction mixtures containing 10  $\mu$ M AdoCbl incubated for 4 h with 0.1  $\mu$ M His<sub>6</sub>-MBP-CbiR, 0.1  $\mu$ M His<sub>6</sub>-MBP, or no protein are shown. An AdoCbl standard is shown at bottom. (C) The corrinoid product of His<sub>6</sub>-MBP-CbiR was purified by HPLC, exposed to light to remove the adenosyl upper ligand, and analyzed by MS. The structure and  $m/z$  values predicted for Cbi-P are shown for comparison. (D) The second product of the *in vitro* reaction with His<sub>6</sub>-MBP-CbiR and AdoCbl was purified by HPLC and analyzed by MS. The structure and  $m/z$  values predicted for  $\alpha$ -ribazole are shown for comparison. (E) Comparison of the UV-Vis spectra before completion (solid line) and after completion (dashed line) of the reaction of His<sub>6</sub>-MBP-CbiR with 30  $\mu$ M AdoCbl shows a decrease in absorbance at 534 nm (arrow). (F) Michaelis-Menten kinetic analysis of His<sub>6</sub>-MBP-CbiR with AdoCbl. Reactions contained 0.3  $\mu$ M His<sub>6</sub>-MBP-CbiR. Points and error bars represent means and standard deviations, respectively. Kinetic constants were determined from two independent experiments, each performed with three technical replicates.

in other bacteria are also found in loci containing similar cobamide biosynthesis enzymes (Fig. 3A; see also Fig. S3).

To determine whether Amuc\_1679 encodes an enzyme that can hydrolyze cobamides, we overexpressed and purified Amuc\_1679 for analysis of its activity *in vitro*. N-terminal hexahistidine (His<sub>6</sub>) and maltose-binding protein (MBP) tags were added to aid in the purification and to increase the solubility of the protein, respectively (Fig. S4A). First, we tested whether a new product was formed when the protein was incubated with coenzyme B<sub>12</sub> (AdoCbl), an active cofactor form of Cbl. We observed complete conversion of AdoCbl to a new corrinoid compound in reactions performed


under anaerobic conditions (Fig. 3B). MS analysis showed that two reaction products, cobinamide-phosphate (Cbi-P) and  $\alpha$ -ribazole, were formed, indicating hydrolysis of the phosphoribosyl bond of AdoCbl (Fig. 3C and D). Notably, Amuc\_1679 targets a bond distinct from the enzyme CbiZ (Fig. 1A) (59). Synthesis of the cobamide from Cbi-P might be a more efficient remodeling process as it would bypass the need to rebuild the aminopropanol linker. In keeping with the tradition of naming cobamide biosynthesis and remodeling enzymes with a “Cbi” prefix, we refer to Amuc\_1679 as CbiR here.

We were able to monitor CbiR activity continuously by measuring the rate of decrease in absorbance at 534 nm ( $A_{534}$ ), as the reaction is characterized by a change in the UV-Vis spectrum that reflects the loss of AdoCbl and formation of AdoCbi-P (Fig. 3E). With this method, we found that the reaction proceeded only in the absence of oxygen and, additionally, that the reaction required the reducing agent dithiothreitol (DTT) and was inhibited by the metal chelator EDTA (Fig. S4B). Although other members of the AP endonuclease 2 superfamily require metals (63–80), CbiR is the only member found to be sensitive to oxygen.

Using the same method, we determined the reaction kinetics of His<sub>6</sub>-MBP-CbiR under steady-state conditions over a range of AdoCbl concentrations (Fig. 3F). On the basis of a fit to the Michaelis-Menten model, the reaction of His<sub>6</sub>-MBP-CbiR with AdoCbl exhibited  $K_M$  and  $k_{cat}$  values for AdoCbl of 194  $\mu$ M and 6.5 min<sup>-1</sup>, respectively. Similarly, His<sub>6</sub>-MBP-CbiR hydrolyzes MeCbl, the active cofactor form used by MetH and other methyltransferases, to MeCbi-P (Fig. S4C), with comparable kinetic parameters (Fig. S4D), indicating that AdoCbl and MeCbl are equally suitable substrates for His<sub>6</sub>-MBP-CbiR.

**A. muciniphila CbiR can hydrolyze several different cobamides *in vitro*.** To determine the substrate selectivity of CbiR, His<sub>6</sub>-MBP-CbiR activity was measured *in vitro* with seven different cobamides. Adenosylated cobamides with purinyl or phenolyl lower ligands do not show UV-Vis spectra distinct from that of AdoCbi-P under the reaction conditions, and thus activity was measured by HPLC. Each cobamide was completely converted to AdoCbi-P following 18 h of incubation, demonstrating that all of the cobamides were substrates for CbiR (Fig. 4A). The specific activities of His<sub>6</sub>-MBP-CbiR with benzimidazolyl and purinyl cobamides were similar, with up to 4-fold differences among them, while higher activities were observed with phenolyl cobamides, though with greater variability between experiments (Fig. 4B). These *in vitro* results seen with CbiR appear to correlate with the remodeling activity found *in vivo* in *A. muciniphila* (Fig. 2C). The specific activities of His<sub>6</sub>-MBP-CbiR are similar to though slightly lower than that previously reported for CbiZ with Ado-pCbl (70 nmol/mg/min [59]), albeit under somewhat different reaction conditions.

**Expression of *cbiR* in *E. coli* enables expanded cobamide use.** Given that the product AdoCbi-P can be used as a precursor for construction of a different cobamide, we hypothesize that CbiR activity enables bacteria to remodel cobamides and therefore to gain access to cobamides in the environment that they otherwise might not be able to use. Because methods for targeted inactivation of genes in *A. muciniphila* have not been established, we used engineered *E. coli* strains to test this hypothesis. Like *A. muciniphila* strain Muc<sup>T</sup>, *E. coli* MG1655 cannot synthesize cobamides *de novo*, but its genome has the cobamide biosynthesis genes *cobT*, *cobS*, *cobU*, and *cobC*, which should allow *E. coli* to convert AdoCbi-P into a cobamide (81). We first tested whether *A. muciniphila* CbiR is functional in *E. coli* grown under aerobic conditions. Expression of untagged CbiR from a plasmid in a  $\Delta cobTSU \Delta cobC$  background did result in the loss of added Cbl, pCbl, [MeAde]Cba, and [Cre]Cba and the formation of two new corrinoid compounds (Fig. 5A). One of the products coeluted with AdoCbi-P (Fig. 5A), and MS analysis confirmed that the dominant ion matches the  $m/z$  values expected for Cbi-P (Fig. S5A). The second product gave  $m/z$  values consistent with Cbi (Fig. S5B), which likely formed intracellularly by hydrolysis of the phosphate group of AdoCbi-P. Neither product was detected in an *E. coli* strain containing the empty vector (Fig. 5A, dashed




**FIG 4** CbiR hydrolyzes many cobamides to form AdoCbi-P. (A) Results of HPLC analysis of *in vitro* reactions performed with different cobamides (10  $\mu$ M), quenched after 18 h, are shown for reaction mixtures containing 0.1  $\mu$ M His<sub>6</sub>-MBP-CbiR (solid lines) or without enzyme (dashed lines). A sample of purified AdoCbi-P is represented at the bottom. (B) Specific activity of His<sub>6</sub>-MBP-CbiR with different cobamide substrates. His<sub>6</sub>-MBP-CbiR (0.3  $\mu$ M) was incubated with a 30  $\mu$ M concentration of each cobamide individually, and the rate of AdoCbi-P production was determined based on HPLC measurements at three time points. The lines represent means and standard deviations of results from three independent experiments.

lines). Therefore, the activity of CbiR that we observed *in vitro* can be recapitulated in *E. coli*, even when it is cultured aerobically.

Catabolism of ethanolamine in *E. coli* requires the cobamide-dependent enzyme ethanolamine ammonia lyase. Because this enzyme uses cobamides in the base-on conformation, in which a nitrogen atom in the lower ligand is coordinated to the cobalt atom (Fig. 1), it can use Cbl as a cofactor but is not functional with [Cre]Cba (82). We took advantage of this selectivity to design a cobamide remodeling-dependent growth assay in *E. coli*. In minimal medium supplemented with [Cre]Cba and 5,6-dimethylbenzimidazole (DMB; the lower ligand of Cbl), with ethanolamine as the sole nitrogen source, *E. coli* should be able to grow only if it can remodel [Cre]Cba to Cbl. Cbl, as expected, promoted growth of *E. coli* under this condition regardless of whether *cbiR* was present (Fig. 5B). In contrast, when [Cre]Cba was added, growth was observed only in the strain expressing *cbiR*, suggesting that CbiR activity enabled *E. coli* to convert [Cre]Cba into Cbl (Fig. 5B). A cobamide with a retention time and *m/z* values matching those of Cbl was detected in a corrinoid extraction of *E. coli* expressing *cbiR* grown with [Cre]Cba and DMB, confirming that cobamide remodeling to Cbl had occurred (Fig. S6). These results demonstrate that expression of CbiR expands the range of cobamides accessible to *E. coli* and suggest that cobamide remodeling may serve a similar purpose in *A. muciniphila*.

**CbiR homologs are present in diverse bacteria.** Analysis of the sequence of CbiR revealed that it is not similar to that of CbiZ or *V. cholerae* CobS, the other enzymes known to have cobamide remodeling activity. Instead, as a member of the AP endonuclease 2 superfamily, CbiR is homologous to the enzymes endonuclease IV, 2-keto-myoinositol dehydratase, and xylose isomerase and to other sugar isomerases and epimerases. A phylogenetic tree of this superfamily shows that the CbiR homologs identified by a BLAST search that are encoded in genomic loci containing cobamide biosynthesis genes form a single, distinct clade (Fig. 6A). Some of the biochemically characterized enzymes in the superfamily require metal cofactors for activity (63–80), and between one and three metal ions, such as Zn<sup>2+</sup>, Fe<sup>2+</sup>, Mg<sup>2+</sup>, and Mn<sup>2+</sup>, are found in nearly all X-ray crystal structures of enzymes from the superfamily (83–97). A metal



**FIG 5** CbiR mediates cobamide remodeling in *E. coli*. (A) CbiR hydrolyzes cobamides in *E. coli*. *A. muciniphila cbiR* was expressed in an *E. coli* strain with the *cobTSU* operon and *cobC* gene deleted to prevent modification of cobamide hydrolysis products. Corrinoid extractions of *E. coli* strains carrying pETmini-*cbiR* (solid lines) or the pETmini empty vector (dashed lines) grown with 10 nM Cbl, pCbl, [MeAde]Cba, or [Cre]Cba were analyzed by HPLC. A sample of purified AdoCbi-P is represented at the bottom. Corrinoids labeled with asterisks were purified for MS analysis (Fig. S5). The large peak at 24.5 min corresponds to a flavin that is present in all of the corrinoid extractions. (B) Expression of *A. muciniphila cbiR* enables growth of *E. coli* on ethanolamine. Wild-type *E. coli* MG1655 harboring pETmini-*cbiR* (black bars) or the pETmini empty vector (white bars) was cultured in minimal medium containing ethanolamine as the sole nitrogen source and 1  $\mu$ M DMB. OD<sub>600</sub> measurements taken after 72 h of growth are shown for unsupplemented cultures and cultures supplemented with 100 nM Cbl or [Cre]Cba. Bars and error bars represent means and standard deviations, respectively, of results from three biological replicates.

cofactor may also be required for CbiR function; in addition to the inhibition by the metal chelator EDTA (Fig. S4B), CbiR homologs contain conserved His, Asp, and Glu residues that, in the characterized members of the superfamily, are involved in metal coordination (Fig. 6B) (86, 90, 93, 94, 96). Significant losses in activity have been observed in site-directed mutants of metal binding residues in AP endonuclease 2 superfamily members (87, 98–106). Similarly, *E. coli* strains expressing *cbiR* alleles with single mutations in many of these conserved residues had little to no AdoCbl hydrolysis activity (Fig. 6C), though effects of these mutations on enzyme folding or stability cannot be ruled out. These results demonstrate that CbiR shares both sequence and functional features common to the members of the AP endonuclease 2 superfamily and represents a new function within the superfamily.

Finally, we investigated the prevalence of CbiR across sequenced organisms by examining genomes with *cbiR* homologs. The *cbiR* gene commonly occurs in the *Akkermansia* genus, as a search of the 191 available genomes in the NCBI database found that 184 have a *cbiR* homolog. Additionally, 282 homologs of *A. muciniphila* CbiR with Expect (E) values below  $10^{-3}$  were identified by BLAST in the genomes of 275 bacterial taxa and 1 archaeal taxon from diverse habitats, including aquatic environments, sewage, digesters, oil spills, bioreactors, soil, and human and animal hosts (see Table S1 in the supplemental material). While 76% are found in the phyla *Chlorobi*, *Chloroflexi*, and *Proteobacteria*, CbiR homologs are also present in 19 additional phyla (Fig. S3; see also Table S1), with relatively few in the PVC superphylum to which *A. muciniphila* belongs. Interestingly, nearly 20% of these taxa contain one or more homologs of *cbiZ* (Table S1), though it remains unknown whether the CbiR and CbiZ homologs in these strains function in cobamide remodeling. Similarly to *A. muciniphila*, 80% of all *cbiR* homologs are located adjacent to genes involved in cobamide biosynthesis (Table S1), suggesting that the majority of *cbiR* homologs function in cobamide remodeling.

## DISCUSSION

Cobamides are considered to be important modulators of mammalian gut ecosystems because they are involved in several metabolic pathways, their production is limited to a subset of prokaryotes, and their diverse structures are differentially accessible to different microbes (54, 107, 108). *A. muciniphila* has been shown to have



structure. Intriguingly, while CbiR differs in sequence from B<sub>12</sub>-binding domains in cobamide-dependent enzymes, the substrate-binding domains of many cobamide-dependent enzymes are comprised of a ( $\beta/\alpha$ )<sub>8</sub> TIM barrel structure, with the C-terminal face interacting with the cobamide cofactor (110–120). Given that CbiR is predicted to have a similar fold, it is possible that the cobamide binding mechanisms of CbiR and these cobamide-dependent enzymes share common features. The yet-to-be-discovered enzyme responsible for remodeling in algae may also be unique, as neither a *P. lutheri* transcriptome (121) nor the *C. reinhardtii* genome contains homologs of CbiR or CbiZ. It therefore appears that cobamide remodeling mechanisms have independently evolved multiple times. Together with the multiple pathways that exist for cobamide biosynthesis, transport, and precursor salvaging (32, 34, 35, 122–128), the addition of CbiR to the growing list of enzymes involved in cobamide metabolism highlights the importance of cobamide physiology in the evolution of bacteria.

In contrast to previously characterized cobamide remodeling enzymes and pathways, CbiR has promiscuous activity, hydrolyzing cobamides irrespective of their lower ligand structure. This activity differs from that of *R. sphaeroides* CbiZ, which does not hydrolyze Cbl *in vitro* (59), and *V. cholerae* CobS, which remodels neither Cbl nor [Cre] Cba (48). In those cases, the cobamide remodeling pathway does not act on a cobamide(s) that can function in its organism's metabolism. In contrast, *A. muciniphila* CbiR readily hydrolyzes pCbl, which functions as a cofactor for methionine synthesis and propionate metabolism in *A. muciniphila* and is the product of Cbi salvaging and cobamide remodeling in the bacterium itself. Thus, it is unclear how *A. muciniphila* prevents CbiR from continuing to hydrolyze pCbl after it is formed via cobamide remodeling. It is possible that pCbl is sequestered intracellularly by binding to MetH or other cobamide-dependent enzymes, such as may have occurred in our ethanolamine-based growth assay in *E. coli* in which *cbiR* was constitutively expressed. Alternatively, CbiR activity could be coupled to cobamide uptake, as has been suggested previously for CbiZ (59, 129). Indeed, similarly to some *cbiZ* homologs, 25% of *cbiR* homologs are located adjacent to genes encoding putative transport proteins, including in *A. muciniphila* strain Muc<sup>T</sup> (see Fig. S3 in the supplemental material). Remodeling in *D. mccartyi* strain 195 shows substrate promiscuity similar to that seen with *A. muciniphila* with respect to the ability to act on numerous, structurally diverse cobamides (56), but the molecular basis of this promiscuity is unclear because its genome carries seven *cbiZ* homologs, none of which has been biochemically characterized. Aside from its activity on pCbl, the broad substrate range of CbiR may benefit *A. muciniphila* by enabling the bacterium to utilize a greater number of the cobamides present in its environment.

The discovery that *A. muciniphila* remodels cobamides leads us to reexamine its ecological roles in the gut. CbiR is found in all 75 of the recently sequenced *A. muciniphila* strains from the human and mouse gut, including the 26 strains that contain the *de novo* cobamide biosynthesis pathway (31, 130). Thus, like cobamide-dependent metabolism (31), cobamide remodeling appears to be nearly universal in *A. muciniphila*. Further, the role of *A. muciniphila* in the gut may be flexible, ranging from producing cobamides *de novo* to remodeling cobamides produced by other microbes, depending on which strains inhabit an individual. Notably, the end product of cobamide remodeling in *A. muciniphila*, pCbl, was the third most abundant corrinoid detected in the human gut in a study of human subjects residing at a single geographic location (42). Interestingly, that study also presented evidence that cobamide remodeling occurs in the human gut, as individuals supplemented with high levels of Cbl showed transiently increased levels of Cbi and of the specific purinyl and phenolyl cobamides that were present in the gut prior to Cbl supplementation. It is possible that *A. muciniphila* is involved in this remodeling activity and contributes to the pool of pCbl in the gut. This, in turn, could modulate the growth or metabolism of other cobamide-requiring bacteria that rely on particular cobamides for their metabolic needs. CbiR may therefore not only expand access to the cobamides available to *A. muciniphila* but also affect those accessible to other bacteria in the gut. Further, homologs of CbiR are found in at

least 276 other microbial taxa and may function similarly in those microbes that inhabit diverse environments. The addition of CbiR to the cobamide remodeling enzymes that have been characterized to date—CbiZ, certain CobS homologs, and the enzyme(s) responsible for remodeling in algae—suggests that cobamide remodeling is more widespread than previously thought.

## MATERIALS AND METHODS

**Media and growth conditions.** *Akkermansia muciniphila* strain Muc<sup>T</sup> (DSM 22959, ATCC BAA-835) was cultivated at 37°C in a vinyl anaerobic chamber (Coy Laboratory Products Inc.) under an atmosphere of approximately 10% CO<sub>2</sub>, 3% H<sub>2</sub>, and 87% N<sub>2</sub>. A synthetic version of a basal mucin-based medium, in which mucin was replaced by soy peptone (16 g/liter), L-threonine (4 g/liter), glucose (2 g/liter), and N-acetylglucosamine (2 g/liter), was supplemented with 1% noble agar and used as a solid medium (21). This synthetic medium also contained L-methionine (125 mg/liter) and omitted rumen fluid. M8 defined medium, developed by Tramontano et al. (131), was used for liquid culturing. We found that the concentration of mucin in this medium (0.5%) was able to abrogate the requirement of methionine addition to the medium for *A. muciniphila* growth. Lowering the concentration to 0.25% resulted in methionine-deplete conditions for *A. muciniphila*, and supplementation with methionine or cobamides restored robust growth. This mucin concentration was used for the MetH-dependent growth assays. However, batch-to-batch variations were seen with mucin such that formulations of media that supported robust growth while remaining methionine-deplete could not always be achieved. Cobamides were omitted from all growth media except when specified. For MetH-dependent growth assays, methionine was omitted from M8 medium.

*Escherichia coli* was cultured at 37°C with aeration in LB medium for cloning, protein expression, and assessing CbiR hydrolytic activity. Ethanolamine-based growth experiments used medium from Scarlett and Turner (38), with B<sub>12</sub> omitted. Media were supplemented with antibiotics at the following concentrations when necessary: kanamycin, 25 mg/liter (pETmini); ampicillin, 100 mg/liter (pET-His<sub>6</sub>-MBP); chloramphenicol, 20 mg/liter (pLysS).

For all *in vivo* experiments involving corrinoids, culture media were supplemented with cyanylated cobamides or (CN)<sub>2</sub>Cbi, which are adenosylated following uptake into cells.

**Genetic and molecular cloning techniques.** The entire *A. muciniphila* *cbiR* open reading frame, except the start codon, was cloned into a modified pET16b vector (132) with N-terminal His<sub>6</sub> and MBP tags added for protein purification. For analysis of CbiR activity in *E. coli*, a minimized 3-kb derivative of pET28a (pETmini) containing a kanamycin resistance (Kan<sup>r</sup>) marker, pBR322 origin, and *rop* gene was used. A constitutive promoter (BBa\_J23100; iGEM) and ribosome binding site (RBS) (BBa\_B0034) were inserted into the vector for expression in *E. coli* MG1655-based strains (complete sequence, TTGACGGCTAGCTCAGTCCTAGGTACAGTGCTAGCGAATTCATACGACTCACTATAAAGAGGAGAAA) and *A. muciniphila* *cbiR* was cloned downstream. Site-directed mutations were introduced into *cbiR* by PCR. All cloning was done by Gibson assembly with *E. coli* XL1-Blue cells (133).

Construction of the *E. coli* MG1655  $\Delta$ *cobTSU*  $\Delta$ *cobC* strain was accomplished using  $\lambda$  Red-based recombination (134) and phage P1 transduction (135). An MG1655  $\Delta$ *cobTSU::Kan<sup>r</sup>* operon deletion was constructed by  $\lambda$  Red-based recombination. The  $\Delta$ *cobC::Kan<sup>r</sup>* allele was transduced into MG1655 via P1 transduction from *E. coli* strain JW0633-1, which was obtained from the Keio collection (136). Kan<sup>r</sup> cassettes were removed by recombination of the flanking FLP recombination target (FRT) sites as described previously (134).

**Chemical reagents.** Porcine gastric mucin was purchased from MilliporeSigma (M1778). AdoCbl (coenzyme B<sub>12</sub>), MeCbl, CNCbl, and (CN)<sub>2</sub>Cbi were purchased from MilliporeSigma.

**Cobamide synthesis, adenosylation, and quantification.** All other cyanylated cobamides used in the study were purified from bacterial cultures, and cobamides were adenosylated and purified as previously described (50, 137). Cyanylated and adenosylated cobamides were quantified as previously described (50). MeCbl was quantified using an extinction coefficient of  $\epsilon_{519} = 8.7 \text{ mM}^{-1} \text{ cm}^{-1}$  (138). AdoCbi-P and MeCbi-P were quantified using the dicyanylated corrinoid extinction coefficient  $\epsilon_{580} = 10.1 \text{ mM}^{-1} \text{ cm}^{-1}$  following conversion to (CN)<sub>2</sub>Cbi-P by incubation with 10 mM KCN in the presence of light (139).

***A. muciniphila* Meth-dependent growth assay.** *A. muciniphila* was precultured for 48 h in M8 medium supplemented with 125 mg/liter methionine. Cells were pelleted by centrifugation, washed twice with phosphate-buffered saline (PBS), and diluted into 80  $\mu$ l M8 medium to an optical density at 600 nm (OD<sub>600</sub>) of 0.02 in a 384-well plate (Nunc) with various concentrations of cobamides and Cbi. The wells were sealed (ThermalSeal RTS; Excel Scientific), and the plate was incubated at 37°C in a BioTek Epoch 2 microplate reader. OD<sub>600</sub> values were measured at regular intervals during growth.

***E. coli* ethanolamine-dependent growth assay.** *E. coli* was precultured 16 h in ethanolamine medium (38) supplemented with 0.02% ammonium chloride. Cells were pelleted by centrifugation, washed three times with 0.85% NaCl, and diluted to an OD<sub>600</sub> of 0.025 in 200  $\mu$ l ethanolamine medium with the specified cobamide additions in a 96-well plate (Corning). The wells were sealed (Breathe-Easy; Diversified Biotech), and OD<sub>600</sub> was monitored at 37°C in a BioTek Synergy 2 microplate reader with shaking.

**Protein expression and purification.** His<sub>6</sub>-MBP-CbiR was expressed in *E. coli* Rosetta(DE3) pLysS. Cells were grown to an OD<sub>600</sub> of 0.4 at 37°C, and expression was induced with 1 mM IPTG (isopropyl- $\beta$ -D-thiogalactopyranoside) for 6 h at 30°C. Cells were lysed by sonication in a buffer containing 20 mM

sodium phosphate, 300 mM NaCl, 10 mM imidazole (pH 7.4), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 1  $\mu$ g/ml leupeptin, 1  $\mu$ g/ml pepstatin, and 1 mg/ml lysozyme. The protein was purified from the clarified lysate using HisPur nickel-nitrilotriacetic acid (Ni-NTA) resin (Thermo Scientific) and eluted with 250 mM imidazole. Purified protein was dialyzed into a buffer containing 25 mM Tris-HCl (pH 8.0), 300 mM NaCl, and 10% glycerol and stored at  $-80^{\circ}\text{C}$ .

**His<sub>6</sub>-MBP-CbiR *in vitro* reactions.** Due to light sensitivity of the compounds, all work involving adenosylated cobamides or MeCbl was performed in the dark or under red or dim white light. Unless specified, the *in vitro* reactions were performed at  $37^{\circ}\text{C}$  in a vinyl anaerobic chamber with the atmosphere described above. The components of the reaction mixtures were 50 mM Tris buffer, 0.3  $\mu$ M purified His<sub>6</sub>-MBP-CbiR, 1 mM DTT, and various concentrations of a cobamide. To prepare the Tris buffer, Tris base was dissolved and equilibrated within the anaerobic chamber. Prior to each experiment, the pH was adjusted with NaOH to account for acidification by the CO<sub>2</sub> present in the atmosphere of the chamber. The pH was adjusted to 8.8 to 8.9 at room temperature (approximately  $24^{\circ}\text{C}$ ), corresponding to a predicted pH range of 8.45 to 8.55 at  $37^{\circ}\text{C}$ . Protein concentrations were determined by absorbance at 280 nm ( $A_{280}$ ).

A BioTek Epoch 2 microplate reader and half-area UV-Star 96-well microplates (Greiner Bio-One) were used for assays monitoring the reaction by absorbance. For these assays, separate 2 $\times$  solutions of AdoCbl and His<sub>6</sub>-MBP-CbiR were prepared in a buffer containing 50 mM Tris and 1 mM DTT. A frozen aliquot of His<sub>6</sub>-MBP-CbiR was thawed inside the anaerobic chamber prior to dilution. The 2 $\times$  AdoCbl solution was preincubated at  $37^{\circ}\text{C}$  for 60 min, while the 2 $\times$  CbiR solution was preincubated at  $37^{\circ}\text{C}$  for 20 min. Volumes of 60  $\mu$ l each of 2 $\times$  AdoCbl and 2 $\times$  His<sub>6</sub>-MBP-CbiR were then mixed in a 96-well plate, with 100  $\mu$ l transferred to a new well prior to performing measurements in the plate reader. Assays with MeCbl were prepared similarly.

Absorbances measured over time at 534 and 527 nm were used to monitor the conversion of AdoCbl to AdoCbi-P and of MeCbl to MeCbi-P, respectively. To enable conversion of  $A_{534}$  values into moles of AdoCbl and of  $A_{527}$  values into moles of MeCbl, extinction coefficient values corresponding to AdoCbl and MeCbl and to purified AdoCbi-P and MeCbi-P were determined in a buffer containing 50 mM Tris (pH 8.8) and 1 mM DTT as follows:  $\epsilon_{534}$  (AdoCbl) =  $7.8 \text{ mM}^{-1} \text{ cm}^{-1}$ ,  $\epsilon_{527}$  (MeCbl) =  $8.0 \text{ mM}^{-1} \text{ cm}^{-1}$ ,  $\epsilon_{534}$  (AdoCbi-P) =  $1.3 \text{ mM}^{-1} \text{ cm}^{-1}$ ,  $\epsilon_{527}$  (MeCbi-P) =  $2.7 \text{ mM}^{-1} \text{ cm}^{-1}$ .

For reactions performed with adenosylated cobamides with different lower ligands monitored by HPLC, cobamides were mixed at 60  $\mu$ M with 50 mM Tris buffer and 1 mM DTT and equilibrated to  $37^{\circ}\text{C}$ . His<sub>6</sub>-MBP-CbiR was equilibrated to  $37^{\circ}\text{C}$  at 0.6  $\mu$ M in a buffer containing 50 mM Tris and 1 mM DTT. Each cobamide and His<sub>6</sub>-MBP-CbiR were mixed in equal volumes, and the reaction mixtures were incubated at  $37^{\circ}\text{C}$ . At three different time points, 100  $\mu$ l of the reaction mixture was removed and mixed with 5  $\mu$ l of 600 mM EDTA to quench the reaction. The protein was removed from samples using Nanosep 10K centrifugal devices (Pall) prior to injection onto the HPLC system. AdoCbi-P levels in the samples were quantified by HPLC by comparison to a standard curve generated with known quantities of purified AdoCbi-P. For reactions involving incubations of 4 to 18 h, initial equilibration at  $37^{\circ}\text{C}$  was not performed.

**Corrinoid extraction.** Cbi salvaging and cobamide remodeling were assessed in *A. muciniphila* by cultivation in M8 medium supplemented with 10 nM Cbi and cobamide, respectively, for 72 h. CbiR cobamide hydrolytic activity with different cobamides in *E. coli* was monitored using the MG1655  $\Delta$ cobTSU  $\Delta$ cobC strain cultivated in LB medium supplemented with 10 nM cobamide for 16 h. Cobamide remodeling in *E. coli* MG1655 was assessed by cultivation in ethanolamine medium supplemented with 100 nM [Cre]Cba and 1  $\mu$ M DMB for 94 h. CbiR mutants were analyzed in *E. coli* MG1655  $\Delta$ cobTSU  $\Delta$ cobC by culturing in LB medium supplemented with 75 nM Cbl for 20 h.

Cyanation of corrinoids extracted from cells for the experiments whose results are shown in Fig. 2A and C (see also Fig. S1 and S2 in the supplemental material) was performed as previously described (56), with 5,000 corrinoid molar equivalents of KCN added. For extractions of adenosylated corrinoids (Fig. 5A and 6C; see also Fig. S5 and S6), cell lysis was performed similarly, with KCN omitted; following removal of cellular debris by centrifugation, deionized water was added to the supernatant to decrease the methanol concentration to 10%. Solid-phase extraction of cyanylated and adenosylated corrinoids with Sep-Pak C<sub>18</sub> cartridges (Waters) was performed as described previously (37). Samples were dried, resuspended in 200  $\mu$ l deionized water (pH 7), and filtered with 0.45- $\mu$ m-pore-size filters (Millex-HV; Millipore) or Nanosep 10K centrifugal devices prior to analysis by HPLC. For extractions involving adenosylated cobamides, all steps were performed in the dark or under red or dim white light.

**HPLC and MS analysis.** Corrinoids were analyzed on an Agilent 1200 series HPLC system equipped with a diode array detector. For the experiments whose results are shown in Fig. 2A and C, 3B, and 4A and B, an Agilent Zorbax SB-Aq column (5- $\mu$ m pore size, 4.6 by 150 mm) was used as previously described (method 2 [58]). For the experiments whose results are shown in Fig. 5A and 6C (see also Fig. S6A), an Agilent Zorbax Eclipse Plus C<sub>18</sub> column (5- $\mu$ m pore size, 9.4 by 250 mm) was used with the following method: solvent A, 0.1% formic acid–deionized water; solvent B, 0.1% formic acid–methanol; 2 ml/min at  $30^{\circ}\text{C}$ ; 18% solvent B for 2.5 min followed by a linear gradient of 18% to 60% solvent B over 28.5 min.

An Agilent 1260 series fraction collector was used for HPLC purification of corrinoids and CbiR reaction products. Purification of CN-pCbl from *A. muciniphila* was performed using the Zorbax SB-Aq column with the method described above. Purification of AdoCbi-P and  $\alpha$ -ribazole from the hydrolysis of AdoCbl by His<sub>6</sub>-MBP-CbiR was performed in two steps. AdoCbi-P and  $\alpha$ -ribazole were first separated and collected on a Zorbax Eclipse XDB C<sub>18</sub> column (5- $\mu$ m pore size, 4.6 by 150 mm) using the following method: solvent A, 10 mM ammonium acetate (pH 6.5); solvent B, 100% methanol; 1 ml/min at  $30^{\circ}\text{C}$ ; 0%

solvent B for 2 min followed by a linear gradient of 0% to 15% solvent B over 1.5 min, 15% to 35% over 6.5 min, 35% to 70% over 2 min, and 70% to 100% over 2 min. Each compound was subsequently run and collected on the Zorbax SB-Aq column with the method described above. Purification of MeCbi-P from the *in vitro* hydrolysis of MeCbl was performed using the Zorbax SB-Aq column with the method described above. The purification of adenosylated hydrolysis products of CbiR from *E. coli* was performed with two rounds of collection; AdoCbi-P and AdoCbi were first separated and collected on the Zorbax Eclipse Plus C<sub>18</sub> column with the method above, and then each compound was run and collected on the Zorbax SB-Aq column using the method described. AdoCbl remodeled from [Cre]Cba in *E. coli* was purified using the Zorbax Eclipse Plus C<sub>18</sub> column with the method described above. Collected compounds were desalted with Sep-Pak C<sub>18</sub> cartridges.

MS analysis was performed on a Bruker linear quadrupole ion trap coupled to a Fourier transform ion cyclotron (LTQ-FT) mass spectrometer at the QB3/Chemistry MS Facility (University of California, Berkeley [UC Berkeley]). Prior to MS analysis, the purified adenosylated and methylated corrinoids were exposed to light to remove the adenosyl and methyl upper ligands, respectively.

**Phylogenetic analysis.** A total of 282 homologs of *A. muciniphila* strain Muc<sup>T</sup> CbiR were identified by BLAST, with E values lower than 10<sup>-3</sup> (see Table S1 in the supplemental material; sequences from other strains of *A. muciniphila* are excluded). A subset of 203 sequences with E values lower than 10<sup>-14</sup> and whose encoding genes were located adjacent to and in the same orientation as a cobamide biosynthesis gene(s) were chosen for phylogenetic analysis performed with the AP endonuclease 2 superfamily (pfam 01261) (Table S1). Sequences were clustered at 0.95 using CD-HIT to reduce the CbiR homolog sequence set by removing subspecies sequence diversity (140). This final set of 178 sequences and *A. muciniphila* CbiR were used to infer a phylogenetic tree with experimentally characterized members of the AP endonuclease 2 superfamily (Table S2). The sequences were aligned with MAFFT (141), and positions with 95% or greater gaps were removed by the use of trimAl (142). A maximum likelihood tree (presented in Fig. 6A) was inferred from this alignment using IQ-TREE v1.6.12 (143) with 1,500 ultrafast bootstraps and visualized in iTOL (144).

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**FIG S1**, PDF file, 0.2 MB.

**FIG S2**, PDF file, 0.2 MB.

**FIG S3**, PDF file, 0.4 MB.

**FIG S4**, PDF file, 0.6 MB.

**FIG S5**, PDF file, 0.3 MB.

**FIG S6**, PDF file, 0.3 MB.

**TABLE S1**, XLSX file, 0.03 MB.

**TABLE S2**, XLSX file, 0.01 MB.

## ACKNOWLEDGMENTS

We thank Amanda Shelton, Amrita Hazra, Kristopher Kennedy, Per Malkus, Raphael Valdivia, and Sebastian Gude for helpful discussions and Kristopher Kennedy and Sebastian Gude for critical reading of the manuscript. We are grateful to Kristopher Kennedy and Sebastian Gude for construction of the pETmini plasmid and the *E. coli* MG1655  $\Delta cobTSU \Delta cobC$  strain, Nina Kirmiz and Gilberto Flores for reagents, and Rita Nichiporuk at the UC Berkeley QB3 Mass Spectrometry Facility for analysis of MS samples.

This work was funded by National Institutes of Health grant R01GM114535.

## REFERENCES

1. Cani PD, Van Hul M, Lefort C, Depommier C, Rastelli M, Everard A. 2019. Microbial regulation of organismal energy homeostasis. *Nat Metab* 1:34–46. <https://doi.org/10.1038/s42255-018-0017-4>.
2. Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaansen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, Guzzetta KE, Jaggar M, Long-Smith CM, Lyte JM, Martin JA, Molinero-Perez A, Moloney G, Morelli E, Morillas E, O'Connor R, Cruz-Pereira JS, Peterson VL, Rea K, Ritz NL, Sherwin E, Spichak S, Teichman EM, van de Wouw M, Ventura-Silva AP, Wallace-Fitzsimons SE, Hyland N, Clarke G, Dinan TG. 2019. The microbiota-gut-brain axis. *Physiol Rev* 99:1877–2013. <https://doi.org/10.1152/physrev.00018.2018>.
3. Hooper LV, Littman DR, Macpherson AJ. 2012. Interactions between the microbiota and the immune system. *Science* 336:1268–1273. <https://doi.org/10.1126/science.1223490>.
4. Libertucci J, Young VB. 2019. The role of the microbiota in infectious diseases. *Nat Microbiol* 4:35–45. <https://doi.org/10.1038/s41564-018-0278-4>.
5. Clemente JC, Ursell LK, Parfrey LW, Knight R. 2012. The impact of the gut microbiota on human health: an integrative view. *Cell* 148:1258–1270. <https://doi.org/10.1016/j.cell.2012.01.035>.
6. Dinan TG, Cryan JF. 2017. The microbiome-gut-brain axis in health and disease. *Gastroenterol Clin North Am* 46:77–89. <https://doi.org/10.1016/j.gtc.2016.09.007>.
7. Durack J, Lynch SV. 2019. The gut microbiome: relationships with disease and opportunities for therapy. *J Exp Med* 216:20–40. <https://doi.org/10.1084/jem.20180448>.
8. Honda K, Littman DR. 2016. The microbiota in adaptive immune homeostasis and disease. *Nature* 535:75–84. <https://doi.org/10.1038/nature18848>.

9. Kho ZY, Lal SK. 2018. The human gut microbiome - a potential controller of wellness and disease. *Front Microbiol* 9:1835. <https://doi.org/10.3389/fmicb.2018.01835>.
10. Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, Thomas M, Wells JM, Langella P. 2013. *Faecalibacterium prausnitzii* and human intestinal health. *Curr Opin Microbiol* 16:255–261. <https://doi.org/10.1016/j.mib.2013.06.003>.
11. O'Callaghan A, van Sinderen D. 2016. Bifidobacteria and their role as members of the human gut microbiota. *Front Microbiol* 7:925. <https://doi.org/10.3389/fmicb.2016.00925>.
12. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. 2008. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 105:16731–16736. <https://doi.org/10.1073/pnas.0804812105>.
13. Derrien M, Belzer C, de Vos WM. 2017. *Akkermansia muciniphila* and its role in regulating host functions. *Microb Pathog* 106:171–181. <https://doi.org/10.1016/j.micpath.2016.02.005>.
14. Zhai Q, Feng S, Arjan N, Chen W. 2019. A next generation probiotic, *Akkermansia muciniphila*. *Crit Rev Food Sci Nutr* 59:3227–3236. <https://doi.org/10.1080/10408398.2018.1517725>.
15. Alam A, Leoni G, Quiros M, Wu H, Desai C, Nishio H, Jones RM, Nusrat A, Neish AS. 2016. The microenvironment of injured murine gut elicits a local pro-restitutive microbiota. *Nat Microbiol* 1:15021. <https://doi.org/10.1038/nmicrobiol.2015.21>.
16. Derrien M, Van Baarlen P, Hooiveld G, Norin E, Müller M, de Vos WM. 2011. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader *Akkermansia muciniphila*. *Front Microbiol* 2:166. <https://doi.org/10.3389/fmicb.2011.00166>.
17. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. 2013. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* 110:9066–9071. <https://doi.org/10.1073/pnas.1219451110>.
18. Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, Ward DV, Grabherr F, Gerner RR, Pfister A, Enrich B, Ciocan D, Macheiner S, Mayr L, Drach M, Moser P, Moschen AR, Perlemuter G, Szabo G, Cassard AM, Tilg H. 2018. Recovery of ethanol-induced *Akkermansia muciniphila* depletion ameliorates alcoholic liver disease. *Gut* 67:891–901. <https://doi.org/10.1136/gutjnl-2016-313432>.
19. Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. 2016. *Akkermansia muciniphila* protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in *ApoE*<sup>-/-</sup> mice. *Circulation* 133:2434–2446. <https://doi.org/10.1161/CIRCULATIONAHA.115.019645>.
20. Ottman N, Reunanen J, Meijerink M, Pietilä TE, Kainulainen V, Klievink J, Huuskonen L, Aalvink S, Skurnik M, Boeren S, Satokari R, Mercenier A, Palva A, Smidt H, de Vos WM, Belzer C. 2017. Pili-like proteins of *Akkermansia muciniphila* modulate host immune responses and gut barrier function. *PLoS One* 12:e0173004. <https://doi.org/10.1371/journal.pone.0173004>.
21. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattarjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. 2017. A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med* 23:107–113. <https://doi.org/10.1038/nm.4236>.
22. Reunanen J, Kainulainen V, Huuskonen L, Ottman N, Belzer C, Huhtinen H, de Vos WM, Satokari R. 2015. *Akkermansia muciniphila* adheres to enterocytes and strengthens the integrity of the epithelial cell layer. *Appl Environ Microbiol* 81:3655–3662. <https://doi.org/10.1128/AEM.04050-14>.
23. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. 2014. An increase in the *Akkermansia* spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* 63:727–735. <https://doi.org/10.1136/gutjnl-2012-303839>.
24. Wu W, Lv L, Shi D, Ye J, Fang D, Guo F, Li Y, He X, Li L. 2017. Protective effect of *Akkermansia muciniphila* against immune-mediated liver injury in a mouse model. *Front Microbiol* 8:1804. <https://doi.org/10.3389/fmicb.2017.01804>.
25. Derrien M, Vaughan EE, Plugge CM, de Vos WM. 2004. *Akkermansia muciniphila* gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. *Int J Syst Evol Microbiol* 54:1469–1476. <https://doi.org/10.1099/ijso.0.02873-0>.
26. Belzer C, Chia LW, Aalvink S, Chamlagain B, Piironen V, Knol J, de Vos WM. 2017. Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B<sub>12</sub> production by intestinal symbionts. *mBio* 8:e00770-17. <https://doi.org/10.1128/mBio.00770-17>.
27. Chia LW, Hornung BVH, Aalvink S, Schaap PJ, de Vos WM, Knol J, Belzer C. 2018. Deciphering the trophic interaction between *Akkermansia muciniphila* and the butyrogenic gut commensal *Anaerostipes caccae* using a metatranscriptomic approach. *Antonie Van Leeuwenhoek* 111:859–873. <https://doi.org/10.1007/s10482-018-1040-x>.
28. Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. 2016. Regulation of immune cell function by short-chain fatty acids. *Clin Transl Immunol* 5:e73. <https://doi.org/10.1038/cti.2016.17>.
29. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. 2016. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. *Cell* 165:1332–1345. <https://doi.org/10.1016/j.cell.2016.05.041>.
30. Louis P, Flint HJ. 2017. Formation of propionate and butyrate by the human colonic microbiota. *Environ Microbiol* 19:29–41. <https://doi.org/10.1111/1462-2920.13589>.
31. Kirmiz N, Galindo K, Cross KL, Luna E, Rhoades N, Podar M, Flores GE. 2019. Comparative genomics guides elucidation of vitamin B<sub>12</sub> biosynthesis in novel human-associated *Akkermansia* strains. *Appl Environ Microbiol* 86:e02117-19. <https://doi.org/10.1128/AEM.02117-19>.
32. Roth JR, Lawrence JG, Bobik TA. 1996. Cobalamin (coenzyme B<sub>12</sub>): synthesis and biological significance. *Annu Rev Microbiol* 50:137–181. <https://doi.org/10.1146/annurev.micro.50.1.137>.
33. Banerjee R, Ragsdale SW. 2003. The many faces of vitamin B<sub>12</sub>: catalysis by cobalamin-dependent enzymes. *Annu Rev Biochem* 72:209–247. <https://doi.org/10.1146/annurev.biochem.72.121801.161828>.
34. Shelton AN, Seth EC, Mok KC, Han AW, Jackson SN, Haft DR, Taga ME. 2019. Uneven distribution of cobamide biosynthesis and dependence in bacteria predicted by comparative genomics. *ISME J* 13:789–804. <https://doi.org/10.1038/s41396-018-0304-9>.
35. Escalante-Semerena JC. 2007. Conversion of cobinamide into adenosylcobamide in bacteria and archaea. *J Bacteriol* 189:4555–4560. <https://doi.org/10.1128/JB.00503-07>.
36. Baker KA, Perego M. 2011. Transcription antitermination by a phosphorylated response regulator and cobalamin-dependent termination at a B<sub>12</sub> riboswitch contribute to ethanalamine utilization in *Enterococcus faecalis*. *J Bacteriol* 193:2575–2586. <https://doi.org/10.1128/JB.00217-11>.
37. Degan PH, Barry NA, Mok KC, Taga ME, Goodman AL. 2014. Human gut microbes use multiple transporters to distinguish vitamin B<sub>12</sub> analogs and compete in the gut. *Cell Host Microbe* 15:47–57. <https://doi.org/10.1016/j.chom.2013.12.007>.
38. Scarlett FA, Turner JM. 1976. Microbial metabolism of amino alcohols. Ethanalamine catabolism mediated by coenzyme B<sub>12</sub>-dependent ethanalamine ammonia-lyase in *Escherichia coli* and *Klebsiella aerogenes*. *J Gen Microbiol* 95:173–176. <https://doi.org/10.1099/00221287-95-1-173>.
39. Shelton AN, Lyu X, Taga ME. 2019. Flexible cobamide metabolism in *Clostridioides (Clostridium) difficile* 630  $\Delta$ erm. *J Bacteriol* 202:e00584-19. <https://doi.org/10.1128/JB.00584-19>.
40. Varel VH, Bryant MP. 1974. Nutritional features of *Bacteroides fragilis* subsp. *fragilis*. *Appl Microbiol* 28:251–257. <https://doi.org/10.1128/AEM.28.2.251-257.1974>.
41. Renz P. 1999. Biosynthesis of the 5,6-dimethylbenzimidazole moiety of cobalamin and of the other bases found in natural corrinoids, p 557–566. In Banerjee R (ed), *Chemistry and biochemistry of B12*. John Wiley & Sons, Inc, New York, NY.
42. Allen RH, Stabler SP. 2008. Identification and quantitation of cobalamin and cobalamin analogues in human feces. *Am J Clin Nutr* 87:1324–1335. <https://doi.org/10.1093/ajcn/87.5.1324>.
43. Girard CL, Berthiaume R, Stabler SP, Allen RH. 2009. Identification of cobalamin and cobalamin analogues along the gastrointestinal tract of dairy cows. *Arch Anim Nutr* 63:379–388. <https://doi.org/10.1080/17450390903020364>.
44. Girard CL, Santschi DE, Stabler SP, Allen RH. 2009. Apparent ruminal synthesis and intestinal disappearance of vitamin B<sub>12</sub> and its analogs in dairy cows. *J Dairy Sci* 92:4524–4529. <https://doi.org/10.3168/jds.2009-2049>.
45. Men Y, Seth EC, Yi S, Crofts TS, Allen RH, Taga ME, Alvarez-Cohen L. 2015. Identification of specific corrinoids reveals corrinoid modification in dechlorinating microbial communities. *Environ Microbiol* 17:4873–4884. <https://doi.org/10.1111/1462-2920.12500>.
46. Keller S, Kunze C, Bommer M, Paetz C, Menezes RC, Svatoš A, Dobbek H,

- Schubert T. 2018. Selective utilization of benzimidazolyl-norcobamides as cofactors by the tetrachloroethene reductive dehalogenase of *Sulfurospirillum multivorans*. *J Bacteriol* 200:e00584-17. <https://doi.org/10.1128/JB.00584-17>.
47. Ma AT, Beld J, Brahmsha B. 2017. An amoebal grazer of cyanobacteria requires cobalamin produced by heterotrophic bacteria. *Appl Environ Microbiol* 83:e00035-17. <https://doi.org/10.1128/AEM.00035-17>.
  48. Ma AT, Tyrell B, Beld J. 2020. Specificity of cobamide remodeling, uptake and utilization in *Vibrio cholerae*. *Mol Microbiol* 113:89–102. <https://doi.org/10.1111/mmi.14402>.
  49. Schubert T, von Reuß SH, Kunze C, Paetz C, Kruse S, Brand-Schön P, Nelly AM, Nüske J, Diekert G. 2019. Guided cobamide biosynthesis for heterologous production of reductive dehalogenases. *Microb Biotechnol* 12:346–359. <https://doi.org/10.1111/1751-7915.13339>.
  50. Sokolovskaya OM, Mok KC, Park JD, Tran JLA, Quanstrom KA, Taga ME. 2019. Cofactor selectivity in methylmalonyl coenzyme A mutase, a model cobamide-dependent enzyme. *mBio* 10:e01303-19. <https://doi.org/10.1128/mBio.01303-19>.
  51. Tanioka Y, Miyamoto E, Yabuta Y, Ohnishi K, Fujita T, Yamaji R, Misono H, Shigeoka S, Nakano Y, Inui H, Watanabe F. 2010. Methyladeninylcobamide functions as the cofactor of methionine synthase in a Cyanobacterium, *Spirulina platensis* NIES-39. *FEBS Lett* 584:3223–3226. <https://doi.org/10.1016/j.febslet.2010.06.013>.
  52. Watanabe F, Nakano Y, Stupperich E. 1992. Different corrinoid specificities for cell growth and cobalamin uptake in *Euglena gracilis* Z. *J Gen Microbiol* 138:1807–1813. <https://doi.org/10.1099/00221287-138-9-1807>.
  53. Yan J, Bi M, Bourdon AK, Farmer AT, Wang PH, Molenda O, Quail AT, Jiang N, Yang Y, Yin Y, Şimşir B, Campagna SR, Edwards EA, Löffler FE. 2018. Purinyl-cobamide is a native prosthetic group of reductive dehalogenases. *Nat Chem Biol* 14:8–14. <https://doi.org/10.1038/nchembio.2512>.
  54. Sokolovskaya OM, Shelton AN, Taga ME. 2020. Sharing vitamins: cobamides unveil microbial interactions. *Science* 369:eaba0165. <https://doi.org/10.1126/science.aba0165>.
  55. Yan J, Şimşir B, Farmer AT, Bi M, Yang Y, Campagna SR, Löffler FE. 2016. The corrinoid cofactor of reductive dehalogenases affects dechlorination rates and extents in organohalide-respiring *Dehalococcoides mccartyi*. *ISME J* 10:1092–1101. <https://doi.org/10.1038/ismej.2015.197>.
  56. Yi S, Seth EC, Men YJ, Stabler SP, Allen RH, Alvarez-Cohen L, Taga ME. 2012. Versatility in corrinoid salvaging and remodeling pathways supports corrinoid-dependent metabolism in *Dehalococcoides mccartyi*. *Appl Environ Microbiol* 78:7745–7752. <https://doi.org/10.1128/AEM.02150-12>.
  57. Helliwell KE, Lawrence AD, Holzer A, Kudahl UJ, Sasso S, Kräutler B, Scanlan DJ, Warren MJ, Smith AG. 2016. Cyanobacteria and eukaryotic algae use different chemical variants of vitamin B<sub>12</sub>. *Curr Biol* 26:999–1008. <https://doi.org/10.1016/j.cub.2016.02.041>.
  58. Mok KC, Taga ME. 2013. Growth inhibition of *Sporomusa ovata* by incorporation of benzimidazole bases into cobamides. *J Bacteriol* 195:1902–1911. <https://doi.org/10.1128/JB.01282-12>.
  59. Gray MJ, Escalante-Semerena JC. 2009. The cobinamide amidohydrolyase (cobyric acid-forming) CbiZ enzyme: a critical activity of the cobamide remodelling system of *Rhodobacter sphaeroides*. *Mol Microbiol* 74:1198–1210. <https://doi.org/10.1111/j.1365-2958.2009.06928.x>.
  60. Ottman N, Davids M, Suarez-Diez M, Boeren S, Schaap PJ, Martins dos Santos VAP, Smidt H, Belzer C, de Vos WM. 2017. Genome-scale model and omics analysis of metabolic capacities of *Akkermansia muciniphila* reveal a preferential mucin-degrading lifestyle. *Appl Environ Microbiol* 83:e01014-17. <https://doi.org/10.1128/AEM.01014-17>.
  61. Miles ZD, McCarty RM, Molnar G, Bandarian V. 2011. Discovery of epoxyqueuosine (oQ) reductase reveals parallels between halorespiration and tRNA modification. *Proc Natl Acad Sci U S A* 108:7368–7372. <https://doi.org/10.1073/pnas.1018636108>.
  62. Daley JM, Zakaria C, Ramot D. 2010. The endonuclease IV family of apurinic/apyrimidinic endonucleases. *Mutat Res* 705:217–227. <https://doi.org/10.1016/j.mrv.2010.07.003>.
  63. Callens M, Kersters-Hilderson H, Van Opstal O, De Bruyne CK. 1986. Catalytic properties of D-xylose isomerase from *Streptomyces violaceoruber*. *Enzyme Microb Technol* 8:696–700. [https://doi.org/10.1016/0141-0229\(86\)90069-4](https://doi.org/10.1016/0141-0229(86)90069-4).
  64. Fan L, Zhang Y, Qu W, Wang J, Shao W. 2011. Cloning and analysis of the xylAB operon and characterization of xylose isomerase from *Thermoanaerobacter ethanolicus*. *Biotechnol Lett* 33:593–598. <https://doi.org/10.1007/s10529-010-0463-x>.
  65. Jia M, Mu W, Chu F, Zhang X, Jiang B, Zhou LL, Zhang T. 2014. A D-psicose 3-epimerase with neutral pH optimum from *Clostridium botteae* for D-psicose production: cloning, expression, purification, and characterization. *Appl Microbiol Biotechnol* 98:717–725. <https://doi.org/10.1007/s00253-013-4924-8>.
  66. Kim HJ, Hyun EK, Kim YS, Lee YJ, Oh DK. 2006. Characterization of an *Agrobacterium tumefaciens* D-psicose 3-epimerase that converts D-fructose to D-psicose. *Appl Environ Microbiol* 72:981–985. <https://doi.org/10.1128/AEM.72.2.981-985.2006>.
  67. Lehmacher A, Bisswanger H. 1990. Comparative kinetics of D-xylose and D-glucose isomerase activities of the D-xylose isomerase from *Thermus aquaticus* HB8. *Biol Chem Hoppe Seyler* 371:527–536. <https://doi.org/10.1515/bchm3.1990.371.1.527>.
  68. Levin JD, Shapiro R, Demple B. 1991. Metalloenzymes in DNA repair. *Escherichia coli* endonuclease IV and *Saccharomyces cerevisiae* Apn1. *J Biol Chem* 266:22893–22898.
  69. Mu W, Chu F, Xing Q, Yu S, Zhou L, Jiang B. 2011. Cloning, expression, and characterization of a D-psicose 3-epimerase from *Clostridium cellulolyticum* H10. *J Agric Food Chem* 59:7785–7792. <https://doi.org/10.1021/jf201356q>.
  70. Mu W, Zhang W, Fang D, Zhou L, Jiang B, Zhang T. 2013. Characterization of a D-psicose-producing enzyme, D-psicose 3-epimerase, from *Clostridium* sp. *Biotechnol Lett* 35:1481–1486. <https://doi.org/10.1007/s10529-013-1230-6>.
  71. Park CS, Kim T, Hong SH, Shin KC, Kim KR, Oh DK. 2016. D-allulose production from D-fructose by permeabilized recombinant cells of *Corynebacterium glutamicum* cells expressing D-allulose 3-epimerase *Flavonifractor plautii*. *PLoS One* 11:e0160044. <https://doi.org/10.1371/journal.pone.0160044>.
  72. Rangarajan M, Hartley BS. 1992. Mechanism of D-fructose isomerization by *Arthrobacter* D-xylose isomerase. *Biochem J* 283:223–233. <https://doi.org/10.1042/bj2830223>.
  73. Salas-Pacheco JM, Urtiz-Estrada N, Martínez-Cadena G, Yasbin RE, Pedraza-Reyes M. 2003. YqfS from *Bacillus subtilis* is a spore protein and a new functional member of the type IV apurinic/apyrimidinic-endonuclease family. *J Bacteriol* 185:5380–5390. <https://doi.org/10.1128/JB.185.18.5380-5390.2003>.
  74. Suekane M, Tamura M, Tomimura C. 1978. Physico-chemical and enzymatic properties of purified glucose isomerases from *Streptomyces olivochromogenes* and *Bacillus stearothermophilus*. *Agric Biol Chem* 42:909–917. <https://doi.org/10.1271/bbb1961.42.909>.
  75. Umemoto Y, Shibata T, Araki T. 2012. D-xylose isomerase from a marine bacterium, *Vibrio* sp. strain XY-214, and D-xylulose production from beta-1,3-xylan. *Mar Biotechnol (NY)* 14:10–20. <https://doi.org/10.1007/s10126-011-9380-9>.
  76. Yoshida K, Yamaguchi M, Morinaga T, Ikeuchi M, Kinehara M, Ashida H. 2006. Genetic modification of *Bacillus subtilis* for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. *Appl Environ Microbiol* 72:1310–1315. <https://doi.org/10.1128/AEM.72.2.1310-1315.2006>.
  77. Zhang W, Fang D, Xing Q, Zhou L, Jiang B, Mu W. 2013. Characterization of a novel metal-dependent D-psicose 3-epimerase from *Clostridium scindens* 35704. *PLoS One* 8:e62987. <https://doi.org/10.1371/journal.pone.0062987>.
  78. Zhang W, Fang D, Zhang T, Zhou L, Jiang B, Mu W. 2013. Characterization of a metal-dependent D-psicose 3-epimerase from a novel strain, *Desmospora* sp. 8437. *J Agric Food Chem* 61:11468–11476. <https://doi.org/10.1021/jf4035817>.
  79. Zhang W, Li H, Zhang T, Jiang B, Zhou L, Mu W. 2015. Characterization of a D-psicose 3-epimerase from *Dorea* sp. CAG317 with an acidic pH optimum and a high specific activity. *J Mol Catal B Enzym* 120:68–74. <https://doi.org/10.1016/j.molcatb.2015.05.018>.
  80. Zhang W, Zhang T, Jiang B, Mu W. 2016. Biochemical characterization of a D-psicose 3-epimerase from *Treponema primitia* ZAS-1 and its application on enzymatic production of D-psicose. *J Sci Food Agric* 96:49–56. <https://doi.org/10.1002/jsfa.7187>.
  81. Lawrence JG, Roth JR. 1995. The cobalamin (coenzyme B<sub>12</sub>) biosynthetic genes of *Escherichia coli*. *J Bacteriol* 177:6371–6380. <https://doi.org/10.1128/jb.177.22.6371-6380.1995>.
  82. Poppe L, Bothe H, Bröker G, Buckel W, Stupperich E, Rétey J. 2000. Elucidation of the coenzyme binding mode of further B<sub>12</sub>-dependent enzymes using a base-off analogue of coenzyme B<sub>12</sub>. *J Mol Catal* 10:345–350. [https://doi.org/10.1016/S1381-1177\(00\)00136-3](https://doi.org/10.1016/S1381-1177(00)00136-3).
  83. Asano R, Ishikawa H, Nakane S, Nakagawa N, Kuramitsu S, Masui R. 2011. An additional C-terminal loop in endonuclease IV, an apurinic/apyrimidinic

- endonuclease, controls binding affinity to DNA. *Acta Crystallogr D Biol Crystallogr* 67:149–155. <https://doi.org/10.1107/S0907444910052479>.
84. Chan HC, Zhu Y, Hu Y, Ko TP, Huang CH, Ren F, Chen CC, Ma Y, Guo RT, Sun Y. 2012. Crystal structures of D-psicose 3-epimerase from *Clostridium cellulolyticum* H10 and its complex with ketohexose sugars. *Protein Cell* 3:123–131. <https://doi.org/10.1007/s13238-012-2026-5>.
  85. Collyer CA, Henrick K, Blow DM. 1990. Mechanism for aldose-ketose interconversion by D-xylose isomerase involving ring opening followed by a 1,2-hydride shift. *J Mol Biol* 212:211–235. [https://doi.org/10.1016/0022-2836\(90\)90316-E](https://doi.org/10.1016/0022-2836(90)90316-E).
  86. Hosfield DJ, Guan Y, Haas BJ, Cunningham RP, Tainer JA. 1999. Structure of the DNA repair enzyme endonuclease IV and its DNA complex: double-nucleotide flipping at abasic sites and three-metal-ion catalysis. *Cell* 98:397–408. [https://doi.org/10.1016/S0092-8674\(00\)81968-6](https://doi.org/10.1016/S0092-8674(00)81968-6).
  87. Jenkins J, Janin J, Rey F, Chiadmi M, van Tilbeurgh H, Lesters I, De Maeyer M, Van Belle D, Wodak SJ, Lauwereys M, Stanssens P, Mrabet NT, Snauwaert J, Matthyssens G, Lambere AM. 1992. Protein engineering of xylose (glucose) isomerase from *Actinoplanes missouriensis*. 1. Crystallography and site-directed mutagenesis of metal binding sites. *Biochemistry* 31:5449–5458. <https://doi.org/10.1021/bi00139a005>.
  88. Kim K, Kim HJ, Oh DK, Cha SS, Rhee S. 2006. Crystal structure of D-psicose 3-epimerase from *Agrobacterium tumefaciens* and its complex with true substrate D-fructose: a pivotal role of metal in catalysis, an active site for the non-phosphorylated substrate, and its conformational changes. *J Mol Biol* 361:920–931. <https://doi.org/10.1016/j.jmb.2006.06.069>.
  89. Lavie A, Allen KN, Petsko GA, Ringe D. 1994. X-ray crystallographic structures of D-xylose isomerase-substrate complexes position the substrate and provide evidence for metal movement during catalysis. *Biochemistry* 33:5469–5480. <https://doi.org/10.1021/bi00184a016>.
  90. Shi R, Pineda M, Ajamian E, Cui Q, Matte A, Cygler M. 2008. Structure of L-xylulose-5-Phosphate 3-epimerase (UlaE) from the anaerobic L-ascorbate utilization pathway of *Escherichia coli*: identification of a novel phosphate binding motif within a TIM barrel fold. *J Bacteriol* 190:8137–8144. <https://doi.org/10.1128/JB.101049-08>.
  91. Tomanicek SJ, Hughes RC, Ng JD, Coates L. 2010. Structure of the endonuclease IV homologue from *Thermotoga maritima* in the presence of active-site divalent metal ions. *Acta Crystallogr Sect F Struct Biol Commun* 66:1003–1012. <https://doi.org/10.1107/S1744309110028575>.
  92. Uechi K, Sakuraba H, Yoshihara A, Morimoto K, Takata G. 2013. Structural insight into L-ribulose 3-epimerase from *Mesorhizobium loti*. *Acta Crystallogr D Biol Crystallogr* 69:2330–2339. <https://doi.org/10.1107/S0907444913021665>.
  93. Whitlow M, Howard AJ, Finzel BC, Poulos TL, Winborne E, Gilliland GL. 1991. A metal-mediated hydride shift mechanism for xylose isomerase based on the 1.6 Å *Streptomyces rubiginosus* structures with xylitol and D-xylose. *Proteins* 9:153–173. <https://doi.org/10.1002/prot.340090302>.
  94. Yoshida H, Yamada M, Nishitani T, Takada G, Izumori K, Kamitori S. 2007. Crystal structures of D-tagatose 3-epimerase from *Pseudomonas cichorii* and its complexes with D-tagatose and D-fructose. *J Mol Biol* 374:443–453. <https://doi.org/10.1016/j.jmb.2007.09.033>.
  95. Yoshida H, Yoshihara A, Gullapalli PK, Ohtani K, Akimitsu K, Izumori K, Kamitori S. 2018. X-ray structure of *Arthrobacter globiformis* M30 ketose 3-epimerase for the production of D-allulose from D-fructose. *Acta Crystallogr F Struct Biol Commun* 74:669–676. <https://doi.org/10.1107/S2053230X18011706>.
  96. Zhang RG, Dementieva I, Duke N, Collart F, Quate-Randall E, Alkire R, Dieckman L, Maltsev N, Korolev O, Joachimiak A. 2002. Crystal structure of *Bacillus subtilis* loll shows endonuclease IV fold with altered Zn binding. *Proteins* 48:423–426. <https://doi.org/10.1002/prot.10159>.
  97. Zhang W, Xu Y, Yan M, Li S, Wang H, Yang H, Zhou W, Rao Z. 2018. Crystal structure of the apurinic/aprimidinic endonuclease IV from *Mycobacterium tuberculosis*. *Biochem Biophys Res Commun* 498:111–118. <https://doi.org/10.1016/j.bbrc.2018.02.181>.
  98. Allen KN, Lavie A, Glasfeld A, Tanada TN, Gerrity DP, Carlson SC, Farber GK, Petsko GA, Ringe D. 1994. Role of the divalent metal ion in sugar binding, ring opening, and isomerization by D-xylose isomerase: replacement of a catalytic metal by an amino acid. *Biochemistry* 33:1488–1494. <https://doi.org/10.1021/bi00172a027>.
  99. Batt CA, Jamieson AC, Vandeyar MA. 1990. Identification of essential histidine residues in the active site of *Escherichia coli* xylose (glucose) isomerase. *Proc Natl Acad Sci U S A* 87:618–622. <https://doi.org/10.1073/pnas.87.2.618>.
  100. Cha J, Cho Y, Whitaker RD, Carrell HL, Glusker JP, Karplus PA, Batt CA. 1994. Perturbing the metal site in D-xylose isomerase. Effect of mutations of His-220 on enzyme stability. *J Biol Chem* 269:2687–2694.
  101. Estevão S, van der Spek PE, van Rossum AMC, Vink C. 2014. Uncoupling of the apyrimidinic/apurinic endonucleolytic and 3'→5' exonucleolytic activities of the Nfo protein of *Mycoplasma pneumoniae* through mutation of specific amino acid residues. *Microbiology (Reading)* 160:1087–1100. <https://doi.org/10.1099/mic.0.077578-0>.
  102. Garcin ED, Hosfield DJ, Desai SA, Haas BJ, Björas M, Cunningham RP, Tainer JA. 2008. DNA apurinic-apyrimidinic site binding and excision by endonuclease IV. *Nat Struct Mol Biol* 15:515–522. <https://doi.org/10.1038/nsmb.1414>.
  103. Kim HJ, Yeom SJ, Kim K, Rhee S, Kim D, Oh DK. 2010. Mutational analysis of the active site residues of a D-psicose 3-epimerase from *Agrobacterium tumefaciens*. *Biotechnol Lett* 32:261–268. <https://doi.org/10.1007/s10529-009-0148-5>.
  104. Waltman MJ, Yang ZK, Langan P, Graham DE, Kovalevsky A. 2014. Engineering acidic *Streptomyces rubiginosus* D-xylose isomerase by rational enzyme design. *Protein Eng Des Sel* 27:59–64. <https://doi.org/10.1093/protein/gzt062>.
  105. Wang WW, Zhou H, Xie JJ, Yi GS, He JH, Wang FP, Xiao X, Liu XP. 2018. *Thermococcus eurythermalis* endonuclease IV can cleave various apurinic/aprimidinic site analogues in ssDNA and dsDNA. *Int J Mol Sci* 20:69. <https://doi.org/10.3390/ijms20010069>.
  106. Zhang W, Jia M, Yu S, Zhang T, Zhou L, Jiang B, Mu W. 2016. Improving the thermostability and catalytic efficiency of the d-Psicose 3-epimerase from *Clostridium bolteae* ATCC BAA-613 using site-directed mutagenesis. *J Agric Food Chem* 64:3386–3393. <https://doi.org/10.1021/acs.jafc.6b01058>.
  107. Degnan PH, Taga ME, Goodman AL. 2014. Vitamin B<sub>12</sub> as a modulator of gut microbial ecology. *Cell Metab* 20:769–778. <https://doi.org/10.1016/j.cmet.2014.10.002>.
  108. Rowley CA, Kendall MM. 2019. To B<sub>12</sub> or not to B<sub>12</sub>: five questions on the role of cobalamin in host-microbial interactions. *PLoS Pathog* 15: e1007479. <https://doi.org/10.1371/journal.ppat.1007479>.
  109. Ovchinnikov S, Park H, Varghese N, Huang PS, Pavlopoulos GA, Kim DE, Kamisetty H, Kyripides NC, Baker D. 2017. Protein structure determination using metagenome sequence data. *Science* 355:294–298. <https://doi.org/10.1126/science.aah4043>.
  110. Berkovitch F, Behshad E, Tang KH, Enns EA, Frey PA, Drennan CL. 2004. A locking mechanism preventing radical damage in the absence of substrate, as revealed by the X-ray structure of lysine 5,6-aminomutase. *Proc Natl Acad Sci U S A* 101:15870–15875. <https://doi.org/10.1073/pnas.0407074101>.
  111. Doukov T, Seravalli J, Stezowski JJ, Ragsdale SW. 2000. Crystal structure of a methyltetrahydrofolate- and corrinoid-dependent methyltransferase. *Structure* 8:817–830. [https://doi.org/10.1016/S0969-2126\(00\)00172-6](https://doi.org/10.1016/S0969-2126(00)00172-6).
  112. Evans JC, Huddler DP, Hilgers MT, Romanchuk G, Matthews RG, Ludwig ML. 2004. Structures of the N-terminal modules imply large domain motions during catalysis by methionine synthase. *Proc Natl Acad Sci U S A* 101:3729–3736. <https://doi.org/10.1073/pnas.0308082100>.
  113. Hagemeyer CH, Krer M, Thauer RK, Warkentin E, Ermler U. 2006. Insight into the mechanism of biological methanol activation based on the crystal structure of the methanol-cobalamin methyltransferase complex. *Proc Natl Acad Sci U S A* 103:18917–18922. <https://doi.org/10.1073/pnas.0603650103>.
  114. Mancia F, Keep NH, Nakagawa A, Leadlay PF, McSweeney S, Rasmussen B, Bösecke P, Diat O, Evans PR. 1996. How coenzyme B<sub>12</sub> radicals are generated: the crystal structure of methylmalonyl-coenzyme A mutase at 2 Å resolution. *Structure* 4:339–350. [https://doi.org/10.1016/S0969-2126\(96\)00037-8](https://doi.org/10.1016/S0969-2126(96)00037-8).
  115. Reitzer R, Gruber K, Jogl G, Wagner UG, Bothe H, Buckel W, Kratky C. 1999. Glutamate mutase from *Clostridium cochlearium*: the structure of a coenzyme B<sub>12</sub>-dependent enzyme provides new mechanistic insights. *Structure* 7:891–902. [https://doi.org/10.1016/S0969-2126\(99\)80116-6](https://doi.org/10.1016/S0969-2126(99)80116-6).
  116. Shibata N, Masuda J, Tobimatsu T, Toraya T, Suto K, Morimoto Y, Yasuoka N. 1999. A new mode of B<sub>12</sub> binding and the direct participation of a potassium ion in enzyme catalysis: X-ray structure of diol dehydratase. *Structure* 7:997–1008. [https://doi.org/10.1016/S0969-2126\(99\)80126-9](https://doi.org/10.1016/S0969-2126(99)80126-9).
  117. Shibata N, Tamagaki H, Hieda N, Akita K, Komori H, Shomura Y, Terawaki S, Mori K, Yasuoka N, Higuchi Y, Toraya T. 2010. Crystal structures of ethanolamine ammonia-lyase complexed with coenzyme B<sub>12</sub> analogs and substrates. *J Biol Chem* 285:26484–26493. <https://doi.org/10.1074/jbc.M110.125112>.

118. Svetlitchnaia T, Svetlitchnyi V, Meyer O, Dobbek H. 2006. Structural insights into methyltransfer reactions of a corrinoid iron-sulfur protein involved in acetyl-CoA synthesis. *Proc Natl Acad Sci U S A* 103:14331–14336. <https://doi.org/10.1073/pnas.0601420103>.
119. Wolthers KR, Levy C, Scrutton NS, Leys D. 2010. Large-scale domain dynamics and adenosylcobalamin reorientation orchestrate radical catalysis in ornithine 4,5-aminomutase. *J Biol Chem* 285:13942–13950. <https://doi.org/10.1074/jbc.M109.068908>.
120. Yamanishi M, Yunoki M, Tobimatsu T, Sato H, Matsui J, Dokiya A, Iuchi Y, Oe K, Suto K, Shibata N, Morimoto Y, Yasuoka N, Toraya T. 2002. The crystal structure of coenzyme B<sub>12</sub>-dependent glycerol dehydratase in complex with cobalamin and propane-1,2-diol. *Eur J Biochem* 269:4484–4494. <https://doi.org/10.1046/j.1432-1033.2002.03151.x>.
121. Keeling PJ, Burki F, Wilcox HM, Allam B, Allen EE, Amaral-Zettler LA, Armbrust EV, Archibald JM, Bharti AK, Bell CJ, Beszteri B, Bidle KD, Cameron BS, Campbell L, Caron DA, Cattolico RA, Collier JL, Coyne K, Davy SK, Deschamps P, Dyhrman ST, Edvardson B, Gates RD, Gobler CJ, Greenwood SJ, Guida SM, Jacobsen JL, Jakobsen KS, James ER, Jenkins B, John U, Johnson MD, Juhl AR, Kamp A, Katz LA, Kiene R, Kudryavtsev A, Leander BS, Lin S, Lovejoy C, Lynn D, Marchetti A, McManus G, Nedelcu AM, Menden-Deuer S, Miceli C, Mock T, Montresor M, Moran MA, Murray S, et al. 2014. The Marine Microbial Eukaryote Transcriptome Sequencing Project (MMETSP): illuminating the functional diversity of eukaryotic life in the oceans through transcriptome sequencing. *PLoS Biol* 12: e1001889. <https://doi.org/10.1371/journal.pbio.1001889>.
122. Campbell GR, Taga ME, Mistry K, Lloret J, Anderson PJ, Roth JR, Walker GC. 2006. *Sinorhizobium meliloti* *bluB* is necessary for production of 5,6-dimethylbenzimidazole, the lower ligand of B<sub>12</sub>. *Proc Natl Acad Sci U S A* 103:4634–4639. <https://doi.org/10.1073/pnas.0509384103>.
123. Gopinath K, Venclovas C, Ioerger TR, Sacchettini JC, McKinney JD, Mizrahi V, Warner DF. 2013. A vitamin B<sub>12</sub> transporter in *Mycobacterium tuberculosis*. *Open Biol* 3:120175. <https://doi.org/10.1098/rsob.120175>.
124. Gray MJ, Escalante-Semerena JC. 2010. A new pathway for the synthesis of a-ribose-phosphate in *Listeria innocua*. *Mol Microbiol* 77:1429–1438. <https://doi.org/10.1111/j.1365-2958.2010.07294.x>.
125. Hazra AB, Han AW, Mehta AP, Mok KC, Osadchiv V, Begley TP, Taga ME. 2015. Anaerobic biosynthesis of the lower ligand of vitamin B<sub>12</sub>. *Proc Natl Acad Sci U S A* 112:10792–10797. <https://doi.org/10.1073/pnas.1509132112>.
126. Rempel S, Gati C, Nijland M, Thangaratnarajah C, Karyolaimos A, de Gier JW, Guskov A, Slotboom DJ. 2020. A mycobacterial ABC transporter mediates the uptake of hydrophilic compounds. *Nature* 580:409–412. <https://doi.org/10.1038/s41586-020-2072-8>.
127. Santos JA, Rempel S, Mous ST, Pereira CT, Ter Beek J, de Gier JW, Guskov A, Slotboom DJ. 2018. Functional and structural characterization of an ECF-type ABC transporter for vitamin B<sub>12</sub>. *Elife* 7:e35828. <https://doi.org/10.7554/eLife.35828>.
128. Wexler AG, Schofield WB, Degnan PH, Folta-Stogniew E, Barry NA, Goodman AL. 2018. Human gut *Bacteroides* capture vitamin B<sub>12</sub> via cell surface-exposed lipoproteins. *Elife* 7:e37138. <https://doi.org/10.7554/eLife.37138>.
129. Gray MJ, Tavares NK, Escalante-Semerena JC. 2008. The genome of *Rhodobacter sphaeroides* strain 2.4.1 encodes functional cobinamide salvaging systems of archaeal and bacterial origins. *Mol Microbiol* 70:824–836. <https://doi.org/10.1111/j.1365-2958.2008.06437.x>.
130. Guo X, Li S, Zhang J, Wu F, Li X, Wu D, Zhang M, Ou Z, Jie Z, Yan Q, Li P, Yi J, Peng Y. 2017. Genome sequencing of 39 *Akkermansia muciniphila* isolates reveals its population structure, genomic and functional diversity, and global distribution in mammalian gut microbiotas. *BMC Genomics* 18:800. <https://doi.org/10.1186/s12864-017-4195-3>.
131. Tramontano M, Andrejev S, Pruteanu M, Klünemann M, Kuhn M, Galardini M, Jouhten P, Zelezniak A, Zeller G, Bork P, Typas A, Patil KR. 2018. Nutritional preferences of human gut bacteria reveal their metabolic idiosyncrasies. *Nat Microbiol* 3:514–522. <https://doi.org/10.1038/s41564-018-0123-9>.
132. Kranzusch PJ, Lee ASY, Wilson SC, Solovkykh MS, Vance RE, Berger JM, Doudna JA. 2014. Structure-guided reprogramming of human cGAS dinucleotide linkage specificity. *Cell* 158:1011–1021. <https://doi.org/10.1016/j.cell.2014.07.028>.
133. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, III, Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat Methods* 6:343–345. <https://doi.org/10.1038/nmeth.1318>.
134. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
135. Silhavy TJ, Berman ML, Enquist LW. 1984. Experiments with gene fusions. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
136. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol* 2:2006.0008. <https://doi.org/10.1038/msb4100050>.
137. Crofts TS, Hazra AB, Tran JL, Sokolovskaya OM, Osadchiv V, Ad O, Pelton J, Bauer S, Taga ME. 2014. Regiospecific formation of cobamide isomers is directed by CobT. *Biochemistry* 53:7805–7815. <https://doi.org/10.1021/bi501147d>.
138. Hogenkamp HPC. 1975. The chemistry of cobalamins and related compounds, p 55. In Babior BM (ed), *Cobalamin biochemistry and pathophysiology*. John Wiley & Sons, Inc, New York, NY.
139. Stupperich E, Eisinger HJ, Kräutler B. 1988. Diversity of corrinoids in acetogenic bacteria. *p*-cresolylcobamide from *Sporomusa ovata*, 5-methoxy-6-methylbenzimidazolylcobamide from *Clostridium formicoaceticum* and vitamin B<sub>12</sub> from *Acetobacterium woodii*. *Eur J Biochem* 172:459–464. <https://doi.org/10.1111/j.1432-1033.1988.tb13910.x>.
140. Fu L, Niu B, Zhu Z, Wu S, Li W. 2012. CD-HIT: accelerated for clustering the next-generation sequencing data. *Bioinformatics* 28:3150–3152. <https://doi.org/10.1093/bioinformatics/bts565>.
141. Katoh K, Rozewicki J, Yamada KD. 2019. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. *Brief Bioinform* 20:1160–1166. <https://doi.org/10.1093/bib/bbx108>.
142. Capella-Gutiérrez S, Silla-Martínez JM, Gabaldón T. 2009. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. *Bioinformatics* 25:1972–1973. <https://doi.org/10.1093/bioinformatics/btp348>.
143. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. 2015. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* 32:268–274. <https://doi.org/10.1093/molbev/msu300>.
144. Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. *Nucleic Acids Res* 44:W242–W245. <https://doi.org/10.1093/nar/gkw290>.